Holen Sie sich die Stockscreener-App
111.73
0.78%
0.86
Handel nachbörslich:
111.73
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences Lands First FDA Approval of a Twice-a-Year HIV PrEP Drug - MedCity News
US FDA approves Gilead's twice-yearly injection for HIV prevention - Deccan Herald
US approves Gilead’s twice-yearly injection to prevent HIV - The Malaysian Reserve
US approves Gilead's twice-yearly injection to prevent HIV - El Paso Inc.
The world's only twice-a-year shot to prevent HIV could stop transmission — if people can get it - Shelton Herald
Gilead Sciences facility video - KTIV
HIV prevention drug lenacapavir approved by FDA as twice-yearly injection - CBS News
FDA approves Gilead's twice-yearly HIV prevention shot - FirstWord Pharma
Gilead Wins Historic Approval for Twice-Yearly HIV Drug - BioSpace
HIV advance: Twice-yearly shot to prevent infection - NZ Herald
Cautious Optimism for Gilead Sciences Amid Yeztugo’s Market Challenges - TipRanks
Gilead's twice-yearly PrEP drug is cleared by FDA - pharmaphorum
FDA approves twice-yearly shot of Gilead drug for HIV prevention - BioPharma Dive
Gilead's HIV Prevention Drug Is 99.9% Effective. Could Politics Derail It? - Investor's Business Daily
US Approves Gilead's Twice-yearly Injection To Prevent HIV - Barron's
FDA Approves Gilead’s Twice-Yearly Injection for HIV Prevention - The Well News
FDA approves 6-month HIV prevention shot - The Hill
Gilead's (GILD) HIV Treatment Yeztugo Gains FDA Approval, Market Potential Expands | GILD Stock News - GuruFocus
FDA Approval Boosts Gilead's (GILD) Prospects in HIV Prevention | GILD Stock News - GuruFocus
Gilead Sciences stock steady as FDA approves twice-yearly HIV prevention - Investing.com UK
Mizuho says Gilead Yeztugo label looks clean - TipRanks
Gilead Sciences (GILD) Gains FDA Nod for HIV Prevention Drug - GuruFocus
FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time. - Barron's
Gilead Sciences’ Yeztugo Approval and Market Expansion Drive Buy Rating - TipRanks
FDA approves powerful HIV prevention drug: What to know about Yeztugo - NBC News
FDA approves the world’s only twice-a-year shot to prevent HIV - mypanhandle.com
FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention - ContagionLive
Gilead’s twice-yearly PrEP injection wins FDA approval, analysts see solid launch ahead - Proactive financial news
Gilead Sciences' HIV Prevention Drug Yeztugo Receives FDA Approval - MarketScreener
Gilead (GILD) Gains FDA Approval for Unique HIV Prevention Drug Yeztugo | GILD Stock News - GuruFocus
Gilead announces FDA approves Yeztugo as twice-a-year HIV prevention option - TipRanks
Gilead’s Twice-a-Year HIV Prevention Shot Wins US FDA Approval - Bloomberg.com
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection - marketscreener.com
Gilead's (GILD) Lenacapavir Advances as HIV Prevention Treatment - GuruFocus
Gilead (GILD) Gains FDA Approval for HIV Prevention Injection | - GuruFocus
Gilead’s twice-yearly HIV prevention shot gets FDA approval - Investing.com Australia
US FDA approves Gilead’s twice-yearly injection for HIV prevention By Reuters - Investing.com
Gilead’s twice-yearly HIV prevention shot gets FDA approval By Investing.com - Investing.com Canada
Gilead stock gains on FDA nod for HIV PrEP drug (GILD:NASDAQ) - Seeking Alpha
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option - CNBC
Gilead won U.S. approval for HIV prevention shot, but when will low-income countries gain sufficient access? - STAT
FDA Says Gilead's Yeztugo Receives FDA Approval For HIV Prevention - marketscreener.com
Gilead Researcher Awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award - CSRwire
Buy, Sell, Or Hold GILD Stock? - Trefis
Gilead Sciences, Inc. (GILD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Fibrotic Diseases Treatment Market Top Companies StudyAbbVie - openPR.com
Gilead's HIV drug could end epidemic, but the company has a dark side - Fast Company
Insider Sell: Andrew Dickinson Sells 2,500 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: ReportGilead Sciences (NASDAQ:GILD) - Benzinga
Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern - Insider Monkey
Levi & Korsinsky Investigates Gilead Sciences, Inc. (GILD) Over Possible Securities Fraud - ACCESS Newswire
GILD ALERT: Levi & Korsinsky Investigates Gilead Sciences, Inc. on Behalf of Shareholders Who Lost Money - ACCESS Newswire
Gilead lays off 36 people after axing Oceanside expansion plan - Fierce Biotech
Gilead Sciences: Strong HIV Market Position and Diversified Growth Strategy Justify Buy Rating - TipRanks
Levi & Korsinsky Investigates Possible Securities Fraud by Gilead Sciences, Inc. (GILD) - ACCESS Newswire
Goldman Sachs Reiterates a Hold Rating on Gilead Sciences (GILD) - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Gilead Sciences, Inc. (GILD) Investors to Inquire about Securities Investigation - ACCESS Newswire
Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline (NASDAQ:GILD) - Seeking Alpha
RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey - Insider Monkey
Gilead Stock Drops After FDA Halts HIV Treatment Trials Over Safety Concerns - Daily Chhattisgarh News
Gilead (GILD) Stock Dips in Trading, But 72% Yearly Gain Highlights Powerful Uptrend - Daily Chhattisgarh News
3.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):